MassDevice.com +5 | The top 5 medtech stories for September 6, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Boehringer Ingelheim touts Stiolto Respimat data
Boehringer Ingelheim yesterday touted results from a Phase III trial showing that its Stiolto Respimat, a drug-device combination helps people with chronic obstructive pulmonary disease walk for longer periods of time while relieving some shortness of breath.
When participants with moderate to severe COPD took Stiolto Respimat, a combination of tiotropium bromide and olodaterol, along with exercise, their exercise capacity increased by 45.8% compared to those receiving a placebo. The Physacto trial is a part of the Tovito Phase III clinical trial, investigating the efficacy of Respimat as a maintenance therapy for COPD. Read more
4. FDA: No evidence of data manipulation in clinical trials for Bayer’s Essure
The FDA said it completed a review of a trade complaint which alleged that Bayer was engaged in clinical trial misconduct and altering data, saying it found no signs of manipulation.
The agency set out to review the allegations, which accused Bayer of clinical trial misconduct, “notably that clinical trial participant...
Source: Mass Device - Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news
More News: Blogging | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chronic Obstructive Pulmonary | Clinical Trials | Health | Heart | Hypertension | International Medicine & Public Health | Lawsuits | Legislation | Marketing | Medical Devices | Spiriva | Sports Medicine | Tiotropium | WHO